NVTA

CMFSwift brought NVTA to the attention of this board some time back. I am continuing my journey to learn more about this company and have invested a small amount. Came across an informative article regarding NVTA and wanted to share with this board.

https://www.cmlviz.com/2019/06/20/NVTA/invitae-nvta-acquires…

Thanks -
Ruhaan

3 Likes

I cant find any news on why the stocked jumped 9% today. I’ve looked into NVTA and like the direction the company announced on June 3. Essentially giving everyone the option to have high quality genetic tests that can be used by their family doctor if one chooses.

June 3
https://ir.invitae.com/news-and-events/press-releases/press-…

A new model for providing genetic health information

Invitae’s service is a new model for providing genetic information by combining high-quality, expert genetic testing with telemedicine-enabled clinical guidance and the ability to share results reports with a consumer’s personal physician. Clinical services are provided through partnerships with well-established telemedicine providers PWN Health and Genome Medical. Invitae’s tests do not need the type of confirmatory testing DTC tests require.

Easy-to-use service provides comprehensive genetic information

The new service allows consumers to initiate and order themselves, and then be paired with a trained, independent clinician who reviews health history and determines the medical appropriateness of their test. Once results are available, the service provides support on next steps, including genetic counseling as appropriate, and also makes it easy for consumers to share their results directly with their personal physician.

The new online service offers broad, expert-curated medical testing across a wide array of health conditions, including nearly all of the company’s test menu. Test results are suitable for making health decisions in collaboration with a clinician.

https://invitae.wistia.com/medias/wkisat3scw

I cant find any news on why the stocked jumped 9% today.

According to streetinsider.com, Cowen analyst Doug Schenkel reiterated an Outperform rating and $30.00 price target on Invitae.

Possible that this moved the price today.

Best, Swift…
Long NVTA